Lunit acquires NZ-based AI diagnostics firm Volpara

It aims to bolster business in the US by purchasing the AI breast cancer diagnostics solutions company at $193 mn

Lunit acquires NZ-based AI diagnostics firm Volpara
Hyun-Ah Oh 1
2023-12-14 14:52:22 5hyun@hankyung.com
Bio & Pharma


South Korean medical AI company Lunit announced on Thursday that it will acquire New Zealand-based AI breast cancer diagnostics solutions company Volpara Health Technologies for $193.07 million.

Under the deal, Volpara is valued at AUD 1.15 per share. This is a 47.4% increase from its previous closing price on the Australian Securities Exchange.

Lunit aims to finance this acquisition through external borrowings and expects the merger process to be complete within the next 3-6 months.

Volpara was Established in 2009 in Wellington. It has specialized in breast cancer diagnostic AI platforms. Its products are used in more than 2,000 medical institutions, accounting for a third of the breast imaging screening facilities in the US. As of last year, Volpara held a 42% market share in the US.

Volpara has about 100 million breast images in the US and other Western countries to develop precise AI models specialized for breast cancer screening.

After the acquisition of Volpara, Lunit plans to continue to acquire an additional 20 million images or more per year.

"This is the fastest and most effective way for Lunit to penetrate the US market," CEO of Lunit Suh Beom-Seok said. "It's the opportunity for us to expedite the development of advanced solutions for early cancer detection."

Write to Hyun-Ah Oh at 5hyun@hankyung.com
#Lunit #Volpara #New Zealand-based #AI breast cancer diagnostics solutions #US market

Lunit selected as contractor for building medical AI platform in Singapore

Lunit selected as contractor for building medical AI platform in Singapore

Lunit's Insight CXR South Korean medical AI company Lunit announced on Friday that it has been selected as the final contractor in the bidding for the establishment of the medical AI platform "AimSG" by SYNAPSE, Singapore's state-owned healthtech agency, aimed at innovating public healthcare se

Lunit gets FDA approval for AI cancer diagnosis solution

Lunit gets FDA approval for AI cancer diagnosis solution

South Korean medical AI company Lunit said on Tuesday its Lunit Insight DBT, an AI imaging diagnosis solution aiding in breast cancer diagnosis, has secured 510(k) pre-market clearance from the US Food and Drug Administration (FDA).This marks Lunit's third FDA approval, joining its AI emergenc

Lunit participates in US gov't Cancer Moonshot

Lunit participates in US gov't Cancer Moonshot

South Korea's medical AI company Lunit announced on Friday it will participate in the US President Joe Biden's cancer-conquering project Cancer Moonshot.The company joins CancerX, a public-private partnership for Cancer Moonshot. CancerX introduced Lunit as the first case for cancer diagnosis

Lunit to supply AI diagnosis solution to Saudi's medical institution

Lunit to supply AI diagnosis solution to Saudi's medical institution

South Korea's medical AI company Lunit announced on Wednesday that it has signed a contract to supply its artificial intelligence (AI) solution for breast cancer diagnosis to hospitals under the Sulaiman Al Habib Medical Group (HMG).HMG is the largest private medical institution in the Middle

Lunit’s AI analysis solution client companies exceed 2,000

Lunit’s AI analysis solution client companies exceed 2,000

South Korean medical AI company Lunit announced on Tuesday that more than 2,000 medical institutions worldwide have adopted its AI-based diagnostic solution called Lunit Insight.Lunit launched its chest X-ray image analysis solution, Lunit Insight CXR, and breast imaging analysis solution, Lun
(* comment hide *}